Conference reports

Ritonavir corrects drug interaction between efavirenz and saquinavir

Lopinavir/r effective in naive patients after three years of treatment

1st IAS Conference on HIV Pathogenesis and Treatment, July 8-11 2001, Buenos Aires, Argentina

Lipodystrophy and metabolic complications

Lipodystrophy and metabolic disturbances

Pharmacology at 1st IAS

Drug-drug interactions

Entry inhibitor updates from the 1st IAS

Structured treatment interruptions (STIs) and structured intermittent therapy (SITs)

Adverse events with antiretrovirals

5th International Workshop on HIV Drug Resistance, 4-8 June 2001, Scottsdale, Arizona

Anti-HIV immune responses and partial viral suppression

HIV resistance, phenotypic drug susceptibility and viral fitness

SWATCH – alternating antiretroviral regimens

Structured treatments interruptions

Importance of additional active drugs for NNRTI-naive patients using NNRTI-based salvage regimens

NNRTI and PI drug plasma levels are as critical as drug sensitivity in achieving treatment success in antiretroviral experienced patients

Increased prevalence of transmission of drug resistant HIV and reduced response in newly infected subjects in nine US cities

Role of codon-69 variants in reduced susceptibility to nucleoside analogues

Selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug naive people

Nucleoside resistance pathways may differ between HIV-1 and HIV-2

Role of Y318F mutation in NNRTI resistance

4th International Conference on Nutrition and HIV Infection and the 2nd European Workshop on Lipodystrophy, April 19-21, 2001, Cannes, France

4th International Conference on Nutrition and HIV Infection and the 2nd European Workshop on Lipodystrophy – pt 2

Keystone Symposium on HIV, March 28-April 3, Keystone, Colorado: more than one way to skin a virus: innate immune factors that suppress HIV replication

2nd International workshop on Clinical Pharmacology of HIV Therapy, 2-4 April, Noordwijk, The Netherlands

First randomised trial shows clinical benefit of TDM for people using nelfinavir or indinavir containing combinations

Clinical Pharmacology of Antiretroviral Therapy, Liverpool, UK , March 2001

8th Conference on Retroviruses and Opportunistic Infections

Paediatric treatment issues at the 8th CROI

8th Conference on Retroviruses and Opportunistic Infections, February 4-8 2001, Chicago, USA

From talk to action in fighting AIDS in the developing countries: 8th Retrovirus Conference opening session

Differentiating within and between drug classes: sometimes it’s toxicity, sometimes its efficacy

Intermittent versus continuous HAART

Viral load “blips” and eventual rebound

Interaction between garlic and saquinavir and underreporting of alternative treatment use

Solid organ transplant in HIV/hepatitis co-infected patients

HIV and women – overview

Update on HIV drug resistance

Update and review of bone studies

Treatment interruptions, structured and unplanned, immunotherapy and what’s in store

Primary infection and treatment issues

Fifth International Congress on Drug Therapy in HIV Infection, 22-26 October 2000, Glasgow, UK

Treatment strategies in 2000: planning first-line (and therefore, second-line) therapy

When should HAART be started?

MDR resistance transmission increases in the UK

Interferon-gamma treatment in azole-resistant oropharyngeal candidiasis

Further reports of avascular necrosis (AVN) and changes in bone mineral density (BMD)

Clinical issues arising from a single treatment interruption

A review of new anti-HIV drugs in development

Antiretroviral therapy in children, women and intravenous drug users

Treatment of HIV+ subjects co-infected with hepatitis B or C: safety and efficacy comparison of ABT 378/r versus nelfinavir from a phase III blinded randomised clinical trial

Interferon-alpha and ribavarin therapy for hepatitis C in HIV coinfected patients

Lack of significant viral load alterations of hepatitis B virus (HBV) and hepatitis C virus (HCV) during treatment with interleukin-2 and HAART

Child protection issues around starting efavirenz in a mother on maintenance methadone

Structured treatment interruptions

Adherence and HAART: unique approaches to evaluating and improving adherence discussed

Reports on lipodystrophy and metabolic complications

Opportunistic infections in the HAART era

2nd International Workshop on Adverse Drug Reactions and Lipodystrophy, Toronto, Canada, 13-15 September 2000

Lipodystrophy: the current state of play

Metabolic effects – bone density and avascular necrosis

Lipoatrophy and facial wasting

Lactic acidosis

Lipodystrophy and metabolic changes in children

Post navigation